The X gene of wild-type hepatitis B virus or integrated DNA has recently been shown to stimulate transcription of a variety of enhancers and promoters. To further delineate the viral sequences responsible for trans-activation in hepatomas, we cloned the single hepatitis B virus insert from human hepatocelluiar carcinoma DNA Ml. The plasmid pMl contains 2004 base pairs of hepatitis'B virus DNA subtype adr, including'truncated preS/S sequences and the enhancer'element.'The X promoter and 422 nucleotides of the X coding region are present. The entire preC/C gene is deleted. In transient cotransfection assays using Chang liver cefls'(CCL 13), pMl DNA exerts' a 6-to 10-fold trans-activating effect on the expression of the pSV2CAT reporter plasmid. The transactivation occurs by stimulation of transcription and is dependent on'the simian virus 40 enhancer in the reporter plasmid. Deletion analysis 'of 
ment.'The X promoter and 422 nucleotides of the X coding region are present. The entire preC/C gene is deleted. In transient cotransfection assays using Chang liver cefls'(CCL 13), pMl DNA exerts' a 6-to 10-fold trans-activating effect on the expression of the pSV2CAT reporter plasmid. The transactivation occurs by stimulation of transcription and is dependent on'the simian virus 40 enhancer in the reporter plasmid. Deletion analysis 'of pMl subclones reveals that the transactivator is'encoded by preS/S and not by X sequences. A frameshift mutation within the preS2 open reading frame shows that this portion is indispensable for the trans-activating function. Initiation of transcription has been mapped to the Si promoter. A comparable trans-activating effect is also observed with cloned wild-type hepatitis B virus sequences similarly truncated. These results show that a transcriptional trans-activator function not present in the intact gene is generated by 3' truncation of integrated hepatitis B virus DNA preS/S sequences.
Strong epidemiological evidence closely links the development of hepatocellular carcinoma (HCC) with chronic hepatitis B virus (HBV) infection (1) . Clonally integrated HBV DNA sequences are found in HCC tissue of more than 90o of hepatitis B surface antigen (HBsAg)-seropositive patients (2) . The integration of HBV DNA is thus considered to be a pathogenetic factor for' tumor development.
In human HCCs cis-activation of oncogenes by HBV promoter or enhancer insertion cannot be regarded as a general mechanism of transformation, although a case is reported where a cellular gene related to a known oncogene might have been activated by integrated HBV DNA (3) . On the other hand, HBV like many other human DNA viruses (4) bears trans-activational potential. The HBV X open reading frame (ORF)'encodes a transcriptional trans-activator that stimulates transcription from its own and many heterologous' promoters in transient transfection assays (5) (6) (7) . The trans-activating function of a tumor-derived HBV subclone was conserved, even when X sequences had been truncated by integration (8) . To In Vitro Transcription and RNase Protection Mapping. The appropriate template plasmid was used to synthesize [32Ip] UTP-labeled riboprobes complementary to the mRNA transcribed from the transfected test plasmids with SP6 polymerase. About 1.2 x 106 CCL 13 cells were cotransfected with 2 ,ug of pSV2CAT and a 10-fold molar excess of test plasmid. Thirty micrograms of total cellular RNA was hybridized to 1 x 106 cpm of the riboprobe for 12-15 hr in 50o (vol/vol) deionized formamide, 40 mM Pipes (pH 6.6), and 400 mM NaCl at 420C. After treatment with RNase A (20 gg/ml) and RNase T1 (5000 units/ml) for 1 hr at 370C, the protected fragments were analyzed on 6% polyacrylamide/8 M urea gels (16) . Autoradiography was performed at -700C.
Chloramphenicol Acetyltransferase (CAT) Assay. One microgram of the reporter plasmid pSV2CAT (17) was cotransfected with a 10-fold molar excess of test plasmid into CCL 13 cells. Forty to 48 hr after transfection, the cells were lysed by sonication. Fifty micrograms of total protein was incubated at 370C for 90 min in the presence of4 mM acetylcoenzyme A and 75 nCi (1 Ci = 37 GBq) of [14C]chloramphenicol. TLC of the reaction products was performed as described (17) . All experiments were repeated four to six times with at least two different preparations of DNA. Acetylation was quantified by cutting out the appropriate portions of the TLC plate and determining the radioactivity in a liquid scintillation counter.
RESULTS
Structural Organization of Clone pMl. Southern blot hybridization of HindIII-digested genomic DNA from HCC tissue Ml revealed a single 4.8-kilobase (kb) fragment that hybridized to HBV DNA (Fig. LA) .
An Ml genomic library was constructed and screened with 32P-labeled HBV DNA. DNA from a plaque-purified positive clone was cloned in the pUC19 vector, yielding plasmid pM1. The nucleotide sequence of pMl was determined by dideoxy sequencing (11 Fig. 2 ). Computer analysis of the sequenced 5' and 3' flanking cellular DNA revealed no homology with any known human genes. Transcriptional Trans-Activating Function of preS/S Sequences. In transient cotransfection assays using the CCL 13 cell line, pM1 DNA stimulated the expression of pSV2CAT DNA 6-to 10-fold as compared to the pUC19 vector DNA alone (Fig. 3) . The reporter plasmid pSV2CAT (17) contains the CAT gene under the control of the simian virus 40 (SV40) early promoter and enhancer, whereas pSV1CAT is lacking the SV40 enhancer (17) . No activation of the CAT gene expression was detectable when pSV1CAT was used. These data suggest that the SV40 enhancer element is necessary for the effect.
Initially assuming that the activation was due to X sequences, we constructed subclone pM35 (Fig. 3) containing HBV DNA from nucleotides 948-17% (i.e., eliminating all but the X ORF and ORF 5 sequences and their regulatory elements). pM35 did not stimulate the CAT gene expression significantly higher than the controls. This might be due to a 1-bp deletion at position 1725 that shifts the reading frame and results in a translational stop at nucleotide 1758. The plasmids pFr and pFI (Fig. 3) covering the 5' and 3' cellular flanking sequences, respectively, exerted no activating function either (Fig. 3) . To test the remaining HBV sequences of pM1 for trans-activational properties, subclones pM18 (nucleotides 717-1236) and pM27 (nucleotides 1372-1796/2703-247) were constructed (Fig. 3) . Whereas plasmid pM18 showed no stimulatory effect on CAT gene expression, pM27, comprising the X gene without its 5' regulatory elements and the preS/S region, exerted a similar activating effect (average of 6.3-fold stimulation) as the entire pM1 clone (Fig. 3) . Subclone pM56, which contains the preS/S sequences (nucleotides 1764-1796 and 2703-217) and both S promoters stimulated CAT gene expression 7.1-fold with respect to the pUC19 control (Fig. 3) . A frameshift mutant pM56fsXhoI constructed by cutting the DNA at the Xho I site (nucleotide 127) within the preS2 ORF lost the trans-activating function (Fig. 3) . These data suggest that the stimulatory effect on CAT gene expression is mediated by means of a trans-acting gene product of preS/S specificity and that the preS2 portion is indispensable for transactivation. The truncated protein would contain the known myristoylation site (26) and the N-terminal amino acids of the large S protein (27) ;. CAT mRNA as reflected by the intensity of the 150-nucleotide RNase-resistant band (Fig. 4) . The 8-fold increase of CAT mRNA as determined by densitometry corresponded to a 7-to 8-fold activation in CAT assays. We therefore conclude that trans-activation by integrated preS/S sequences occurs at the transcriptional level.
(")
Since both S gene promoters were contained in all transactivating clones, we performed RNase protection mapping of preS/S-specific mRNAs to determine the transcription start sites. Analysis of mRNA isolated from CCL 13 cells transfected with pM27 or pM56 revealed two protected RNAs initiating at the S1 promoter (Fig. 5) . One transcript most likely started at the previously described initiation site (20) and a second one started about 30 nucleotides upstream. Transcripts arising from the S2 promoter were not detected.
Transient Expression of a Viral-Cellular Fusion Transcript by pMl DNA. Northern blotting oftotal and polyadenylylated RNA isolated from CCL 13 cells transiently transfected with pM1 DNA showed a distinct transcript of 2.5 kb that hybridized to total HBV (Fig. 1B, lane 1) and preS/S (Fig. 1B, lane  2) but not to X DNA (Fig. 1B, lane 3) . The size of the transcript suggested a read-through from viral to flanking 3' A preSl S2 S OF cellular sequences and probably termination at a sequenced poly(A) site identified "s1700 bp downstream of the viralcellular junction. Trans-Activation by Cloned Wild-Type HBV preS/S Sequences. To test for the trans-activational potential of the corresponding cloned wild-type HBV sequences, plasmid pVPS was constructed. It comprises the HBV nucleotides 2512-217 (i.e., the complete preS region and the S sequences truncated at exactly the same position as in the integrated HBV DNA in pM56). When tested for CAT activity, pVPS exerted a 5-to 8-fold activating effect that equaled the level of stimulation by the integrated counterpart (Fig. 3) . In contrast, cloned full-length wild-type preS/S sequences contained in clone pHBS (nucleotides 2434-833) did not stimulate CAT gene expression ( Fig. 3; refs. 6 and 30) . Thus, even in the unintegrated state, the preS/S gene exerts a transactivating function only when 3' truncated.
DISCUSSION
We provide evidence for the presence of a previously unreported transcriptional trans-activator within the preS/S region of HBV. The single-copy HBV DNA insert of a human .: i.
HCC was cloned. The clone, pMl, contains truncated preS/S and X sequences. A major deletion of 905 bp (HBV nucleotides 1797-2702) led to the elimination of the C gene.
The entire cloned pM1 DNA was shown to stimulate transient expression of the CAT gene. By subcloning, it was demonstrated that the stimulatory effect was not encoded within the X ORF. A 1-bp deletion (HBV nucleotide 1725) gives rise to a frameshift whereby a functional X protein cannot be expressed. This is the likely reason for the lack of activity of the X sequences. On the other hand, stimulation of pSV2CAT expression in subclone pM56, which contained 522 bp of the preS and 63 bp of the S ORF, was comparable to that of pM1. The preS/S region of HBV sequences is, therefore, sufficient for the stimulatory effect.
The HBV preS/S region has recently been reported to contain an enhancer-like element (31) . It was, therefore, arguable that the observed stimulation might be due to a cis-acting effect mediated by the linkage of test and reporter plasmid during cotransfection. When the enhancerless reporter plasmid pSV1CAT was cotransfected with the test plasmids, no stimulation was observed. Furthermore, the effect was abolished when pM56fsXhoI, which bears a frameshift mutation within the preS2 ORF, was used. Taken together, these data suggest that the CAT expression is stimulated in trans by a trans-activator protein encoded within the preS/S region and that the preS2 portion is necessary for the effect.
RNase protection analysis of CAT mRNA revealed that trans-activation occurred at the level of transcription. Transcription of preS/S-specific mRNA started exclusively at the S1 promoter. The RNase-resistant fragment of 620 nucleotides (Fig. 5) corresponds to a transcript possibly starting at a previously described initiation site (20) ; the second protected fragment of -650 nucleotides represents a mRNA that originates at an additional start site close to the TATA box of the S1 promoter. The S2 promoter at which the majority of S transcripts initiate (32) was not active. This may be due to a point mutation (HBV nucleotide 3118) in the part of the S2 promoter region that has recently been shown to act as a repressor element for S1 transcription (33) . Inactivation of this element by mutation may result in an altered promoter usage. Alternatively, the switching of transcription from the S2 to the S1 promoter may be due to cell type-specific properties of CCL 13 (34, 35) . According to our results, the dissociation of 3' sequences assigns a newly generated trans-activating function to the HBV preS/S region. During virus replication, a truncated S protein with trans-activational properties could be encoded by a spliced transcript. Such transcripts have been recently reported for HBV (36, 37 
